Stroke in Children : Recognition,Treatment,and Future Directions



Gabrielle de Veber , E.Steve Roach , Anthony R. Riela , and Max  Wiznitzer


     Childhood stoke is increasingly recognized , but studies remain largly descriptive . Important differences from adult stroke include the following: (1) frequently delayed or missed diagnosis,(2) heterogenous and overlapping risk factors , and (3) developmental differences in the cerebrovascular , neurologic , and coagulation systems . These aspects limit the extrapolation of the results of adult stroke research and present challenges in caring for children with stroke . The incidence of childhood ischemic stroke exceeds 3.3 in 100,000 children per year , more than double the estimates from past decades . The increased incidence reflects,  in part , increased survival in previously fatal conditions predisposing to stroke , including congenital heart disease , stickle cell anemia , and leukemia . Risk factors for stroke are recognized in more than 75% of children . Common risk factors include congenital heart disease and sickle cell disease . Progressive arteriopathies , including vasculitis and moyamoya syndrome , are rate in children with stroke ; however , transient arteriopathies including post-varicella angiopathy are increasingly recognized . Prothrombotic abnormalities are frequently present but of unclear significance. Adverse outcomes after childhood stroke , including death in 10% , recurrence in 20% , and neurologic deficits in two thirds of survivors could be reduced with available stroke treatments . Aggressive prehospital emergency care and transfer could improve access to hupeacute stroke therapies including tPA . Currently , the diagnosis is delayed by more than 24 hours from onset in most children . As in adults , tPA will likely produce unacceptable rates of intracerebral hemmorrhage unless given within 3 hours of stroke symptom onset. The appropriate choices for in hospital treatment and secondary preventative strategies , including aspitin and anticoagulants , are controversial.Empiric recommendations are published; however , age-appropriate clinical trials are urgently needed .The large multiational networks of investigators necessary for designing and conducting these future trials are now being formed.


Journal of Child Neurology

Copyright©  2000 by W.B.Saunders Company

Seminars in Pediatric Neurology,Vol 7, No 4 (December), 2000:pp 309-317